7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Pyxis Oncology, Inc.
(NASDAQ:PYXS) 

PYXS stock logo

Pyxis Oncology, Inc., a preclinical stage biotechnology company, engages in the development of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies to treat cancers. Its preclinical products pipeline includes PYX-201, a site-specific investigational ADC targeting onco-fetal ...

Founded: 2018
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
Pyxis Oncology . Days Payable Outstanding ttm (DPO)
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 082.15164.29246.44328.59410.73492.88575.03
Pyxis Oncology . Op Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -4.26-3.65-3.04-2.43-1.83-1.22-0.610
Pyxis Oncology . Free Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -4.46-3.82-3.19-2.55-1.91-1.27-0.640
Pyxis Oncology . Cash Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.981.972.953.934.925.96.88
Pyxis Oncology . (GAAP) P/E ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -8.11-6.95-5.79-4.63-3.47-2.32-1.160
Pyxis Oncology . P/B ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.280.560.851.131.411.691.97
No extra charts and metrics for this ticker.